Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
On January9, 2017, Intersect ENT, Inc. (the Company) issued a
press release announcing its preliminary expectations of revenue
for the fourth quarter of 2016 and the year ended December31,
2016 as well as revenue guidance for the first quarter of 2017
and the year ending December31, 2017. A copy of the Company press
release is furnished and attached as Exhibit 99.1.
The information in this Item7.01 and Exhibit 99.1 of this Current
Report on Form 8-K are being furnished and shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934 as amended (Exchange Act), or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended (Securities Act). The
information in this Item7.01 and Exhibit 99.1 shall not be deemed
incorporated by reference in any filing under the Securities Act,
or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item9.01 |
Financial Statements and Exhibits. |
(d) |
Exhibits |
|
|
|
|
| 99.1 |
Press release entitled Intersect ENT Reports Preliminary Q4 and Year 2016 Revenue dated January 9, 2017. |
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant. Intersect ENT, Inc. (NASDAQ:XENT) Recent Trading Information
Intersect ENT, Inc. (NASDAQ:XENT) closed its last trading session up +1.20 at 13.05 with 341,196 shares trading hands.